NCT04397510 is a Phase 4 clinical trial of Heparin in Covid-19, sponsored by Frederick Health.

Who is sponsoring NCT04397510?

NCT04397510 is sponsored by Frederick Health.

What drugs are being tested in NCT04397510?

Interventions in NCT04397510: Heparin, 0.9% Sodium-chloride.

What condition does NCT04397510 study?

NCT04397510 studies Covid-19, ARDS, Human, Acute Lung Injury.

Is NCT04397510 still recruiting?

NCT04397510 is currently terminated. Last updated 3 April 2024.

Last reviewed 2024-04-03 · How we verify

NCT04397510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Terminated Phase 4 Last updated 3 April 2024

What this trial tests

Phase 4 trial testing Heparin in Covid-19 in 13 participants. Terminated before completion.

Timeline

1 June 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Frederick Health
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	13
Start date	1 June 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

Heparin (HEPARIN) — full drug profile →
0.9% Sodium-chloride

Conditions studied

Covid-19 — all drugs for Covid-19 →
ARDS, Human — all drugs for ARDS, Human →
Acute Lung Injury — all drugs for Acute Lung Injury →

Sponsor

Frederick Health

Who can join

18 and older, any sex, with Covid-19 or ARDS, Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Design of therapeutic biomaterials to control inflammation.
Tu Z, Zhong Y, Hu H, Shao D, et al · · 2022 · cited 314× · PMID 35251702 · DOI 10.1038/s41578-022-00426-z
COVID-19 and thrombosis: From bench to bedside.
Ali MAM, Spinler SA. · · 2021 · cited 140× · PMID 33338635 · DOI 10.1016/j.tcm.2020.12.004
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, et al · · 2021 · cited 126× · PMID 33741176 · DOI 10.1016/j.jacc.2021.02.035
Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.
Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. · · 2021 · cited 112× · PMID 33228447 · DOI 10.1161/jaha.120.019650
Thromboinflammation in COVID-19 acute lung injury.
Mitchell WB. · · 2020 · cited 54× · PMID 32653469 · DOI 10.1016/j.prrv.2020.06.004
Prophylactic anticoagulants for people hospitalised with COVID-19.
Flumignan RL, Tinôco JDS, Pascoal PI, Areias LL, et al · · 2020 · cited 42× · PMID 33502773 · DOI 10.1002/14651858.cd013739
Anticoagulants for people hospitalised with COVID-19: a rapid review
Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, et al · · 2022 · cited 41× · PMID 35244208 · DOI 10.1002/14651858.cd013739.pub2
Acute Respiratory Distress Syndrome and COVID-19: A Literature Review.
Hussain M, Khurram Syed S, Fatima M, Shaukat S, et al · · 2021 · cited 38× · PMID 34992415 · DOI 10.2147/jir.s334043

Verify or expand the search:

Other trials of Heparin

Trials testing the same drug.

NCT06453876 — PERCUTANEOUS EMBOLECTOMY, ULTRASOUND ASSISTED LOW DOSE THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBO · Phase 3 · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT06676085 — A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation · NA · recruiting
NCT06549842 — Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial · NA · completed
NCT05848713 — AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia · Phase 3 · recruiting

Other recruiting trials for Covid-19

Currently open trials in the same condition.

NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting
NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting

Other Frederick Health trials

Trials by the same sponsor.

NCT04723563 — Nebulized Heparin for the Treatment of COVID-19 · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04397510 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Frederick Health
Last refreshed: 3 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04397510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing